These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17108893)

  • 41. A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat.
    Lilly PD; Andersen ME; Ross TM; Pegram RA
    Toxicol Appl Pharmacol; 1998 Jun; 150(2):205-17. PubMed ID: 9653052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma and Hepatic Concentrations of Chemicals after Virtual Oral Administrations Extrapolated Using Rat Plasma Data and Simple Physiologically Based Pharmacokinetic Models.
    Kamiya Y; Otsuka S; Miura T; Takaku H; Yamada R; Nakazato M; Nakamura H; Mizuno S; Shono F; Funatsu K; Yamazaki H
    Chem Res Toxicol; 2019 Jan; 32(1):211-218. PubMed ID: 30511563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chloroform: exposure estimation, hazard characterization, and exposure-response analysis.
    Meek ME; Beauchamp R; Long G; Moir D; Turner L; Walker M
    J Toxicol Environ Health B Crit Rev; 2002; 5(3):283-334. PubMed ID: 12162870
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PBPK modeling to support risk assessment of pyrethroid exposure in French pregnant women.
    Thépaut E; Bisson M; Brochot C; Personne S; Appenzeller BMR; Zaros C; Chardon K; Zeman F
    Environ Res; 2024 Jun; 251(Pt 1):118606. PubMed ID: 38460660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the influence of chloroacetic acids on the pharmacokinetics of trihalomethanes in the rat.
    St-Pierre A; Krishnan K; Tardif R
    J Toxicol Environ Health A; 2003 Dec; 66(23):2267-80. PubMed ID: 14612337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Passive exposures of children to volatile trihalomethanes during domestic cleaning activities of their parents.
    Andra SS; Charisiadis P; Karakitsios S; Sarigiannis DA; Makris KC
    Environ Res; 2015 Jan; 136():187-95. PubMed ID: 25460636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer risk assessment from trihalomethanes in drinking water.
    Wang GS; Deng YC; Lin TF
    Sci Total Environ; 2007 Nov; 387(1-3):86-95. PubMed ID: 17727920
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment.
    Lipscomb JC; Haddad S; Poet T; Krishnan K
    Adv Exp Med Biol; 2012; 745():76-95. PubMed ID: 22437814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and evaluation of a harmonized whole body physiologically based pharmacokinetic (PBPK) model for flutamide in rats and its extrapolation to humans.
    Sharma RP; Kumar V; Schuhmacher M; Kolodkin A; Westerhoff HV
    Environ Res; 2020 Mar; 182():108948. PubMed ID: 31841869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of potential toxicity from co-exposure to three CNS depressants (toluene, ethylbenzene, and xylene) under resting and working conditions using PBPK modeling.
    Dennison JE; Bigelow PL; Mumtaz MM; Andersen ME; Dobrev ID; Yang RS
    J Occup Environ Hyg; 2005 Mar; 2(3):127-35. PubMed ID: 15764536
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of probabilistic modeling within a physiologically based pharmacokinetic model to predict sulfamethazine residue withdrawal times in edible tissues in swine.
    Buur J; Baynes R; Smith G; Riviere J
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2344-51. PubMed ID: 16801411
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma concentrations of melengestrol acetate in humans extrapolated from the pharmacokinetics established in in vivo experiments with rats and chimeric mice with humanized liver and physiologically based pharmacokinetic modeling.
    Tsukada A; Suemizu H; Murayama N; Takano R; Shimizu M; Nakamura M; Yamazaki H
    Regul Toxicol Pharmacol; 2013 Apr; 65(3):316-24. PubMed ID: 23395687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetic modeling of β-chloroprene metabolism: Probabilistic in vitro-in vivo extrapolation of metabolism in the lung, liver and kidneys of mice, rats and humans.
    Yang Y; Himmelstein MW; Clewell HJ
    Toxicol In Vitro; 2012 Sep; 26(6):1047-55. PubMed ID: 22543297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A.
    Yang X; Doerge DR; Teeguarden JG; Fisher JW
    Toxicol Appl Pharmacol; 2015 Dec; 289(3):442-56. PubMed ID: 26522835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new method for generating distributions of biomonitoring equivalents to support exposure assessment and prioritization.
    Phillips MB; Sobus JR; George BJ; Isaacs K; Conolly R; Tan YM
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):434-42. PubMed ID: 24845241
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physiologically-based pharmacokinetic modeling of genistein in rats, Part I: Model development.
    Schlosser PM; Borghoff SJ; Coldham NG; David JA; Ghosh SK
    Risk Anal; 2006 Apr; 26(2):483-500. PubMed ID: 16573635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue dosimetry expansion and cross-validation of rat and mouse physiologically based pharmacokinetic models for trichloroethylene.
    Keys DA; Bruckner JV; Muralidhara S; Fisher JW
    Toxicol Sci; 2003 Nov; 76(1):35-50. PubMed ID: 12915716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition.
    Arnold SM; Morriss A; Velovitch J; Juberg D; Burns CJ; Bartels M; Aggarwal M; Poet T; Hays S; Price P
    Regul Toxicol Pharmacol; 2015 Mar; 71(2):235-43. PubMed ID: 25543108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Estimation of placental and lactational transfer and tissue distribution of atrazine and its main metabolites in rodent dams, fetuses, and neonates with physiologically based pharmacokinetic modeling.
    Lin Z; Fisher JW; Wang R; Ross MK; Filipov NM
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):140-58. PubMed ID: 23958493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.